Drug that prevents hot flushes to be available on NHS in England
AI Summary
A new drug, Veoza (fezolinetant), has been approved for use on the NHS in England to treat hot flushes in menopausal women. The National Institute for Health and Care Excellence (NICE) authorized the drug for women for whom hormone replacement therapy (HRT) is unsuitable due to medical history or personal preference. Affecting approximately 70% of menopausal women, hot flushes can significantly impact quality of life. Fezolinetant, a non-hormonal treatment taken once daily, works by blocking nerve pathways in the brain that trigger hot flushes and night sweats. It is estimated that around 500,000 women will be eligible for the treatment, providing an alternative for those unable to use HRT. While HRT remains the first-line treatment, fezolinetant addresses a critical need for women seeking non-hormonal relief.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.